echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > 19 listed pharmaceutical companies revenue of 10 billion yuan, the top five have who

    19 listed pharmaceutical companies revenue of 10 billion yuan, the top five have who

    • Last Update: 2020-04-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Pharmaceutical Network Industry Dynamics : According to Tonghuashun statistics, 130 pharmaceutical and biological listed enterprises that have published their 2019 annual reports, the revenue of 10 billion yuan of enterprises reached 19, the top 5 are Shanghai Pharmaceuticals, Baiyunshan, National Pharmaceutical Stakes, Nanjing Pharmaceuticals and Heavy Drugs Holdings had revenues of RMB186.566 billion, RMB64.952 billion, RMB44.645 billion, RMB37.156 billion and RMB33.844 billion, respectively
    In addition to Baiyunshan, the other four companies belong to the pharmaceutical business industryAmong them, Shanghai Pharmaceutical and State Pharmaceutical shares are two of China's four major pharmaceutical circulation enterprisesHowever, Baiyunshan also has a pharmaceutical circulation business, subsidiary Guangzhou Pharmaceutical Co., Ltdfor the south Of China's large pharmaceutical circulation enterprises, in September 2019 Baiyunshan issued a public announcement, to spin off Guangzhou Pharmaceutical to Hong Kong stock listingThe revenue of 19 listed pharmaceutical companies broke 10 billion yuan (Photo: Pharmaceutical Network) Shanghai Pharma's industrial endogenous growth accelerated in 2019, and the research and development efforts increased in 2019 Shanghai Pharmaceutical's main business to achieve revenue of 186.566 billion yuan, up 17.3% YoYAmong them, the pharmaceutical industry 23.49 billion yuan, an increase of 20.7% year-on-yearPharmaceutical business was RMB163.08 billion, up 16.8% YoY
    In terms of profit, the company's net profit for 2019 was RMB4.08 billion, while net profit of the company was RMB3.46 billion, up 30.5% YoYIn the net profit of the mother, the pharmaceutical industry contributed 2.08 billion yuan, up 24.5% yoyBusiness contributed 2.23 billion yuan, up 26.8% year-on-year
    During the reporting period, net operating cash flow was RMB6.02 billion, up 92.1% YoYAmong them, the pharmaceutical industry's net inflow was RMB3.46 billion, up 40.1% YoYThe net inflow of pharmaceutical business was RMB3.07 billion, up 211.9% YoYThe number of the company's more than 100 million products increased from 31 in 2018 to 35, of which more than 500 million varieties increased to 9, mainly in cardiovascular, systemic anti-infection, immunomodulation, blood and hematopoietic organs and other fields
    In 2019, the company's main product sales increased steadily, compared with last year's new 4 varieties, 5 product regulations approved, 24 new varieties, 29 product regulations declared, solidified the domestic market At the same time, the company accelerated the pace of internationalization, a number of API approved overseas, the addition of 2 drugs to obtain the United States ANDA approval, overseas sales revenue growth In 2019, we will continue to increase research and development investment, with cost-based investment increasing by 27.2% YoY, including 15 products, 16 innovative drug projects with indications in the clinical research and clinical trial application stage, and the introduction of 8 new products, the official opening of the research and development center in San Diego, the United States, domestic companies have reached a new agreement with seven universities and hospitals, research institutes and other institutions, respectively, in the raw materials, Chinese medicine, new products, new products, new technology development, cell therapy, innovation and transformation of science and research and other fields
    Baiyunshan will continue to promote capital operations and investment mergers and acquisitions, and help extend the expansion According to the 2019 annual report released by Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd., operating income in 2019 was RMB64.952 billion, up 53.79 percent YoY, while net profit attributable to the Company's shareholders was RMB3.189 billion, a decrease of 7.33 percent YoY
    Bai Yunshan pointed out that the net profit attributable to the shareholders of the Company decreased year-on-year year-on-year due to the fact that the company's acquisition of the pharmaceutical company and Wang Laoji Pharmaceuticals was included in the scope of the company's merger, the proceeds from the company's acquisition of the pharmaceutical company and Wang Laoji Pharmaceuticals, and the income from the change in fair value of the company held by the Company were non-taxable items;
    In the 2020 development strategy and work plan, Bai Jiashan said, to further increase investment in scientific research, accelerate the development of innovative drugs, biological drugs, high-end generic drugs and other aspects of research and development
    In its annual report, Baiyunshan said the company will continue to promote capital operations and investment in mergers and acquisitions, help extended expansion, "promote pharmaceutical companies to separate to overseas listing-related work, optimize the capital structure, broaden financing channels; "China Pharmaceutical shares deeply dig into the market growth potential, innovative supply chain value-added services China Pharmaceutical son recently released the 2019 annual report, the announcement shows that the reporting period achieved revenue of 44.645 billion yuan, up 15.24% YoY;
    It is understood that in 2019, under the leadership of the board of directors, the national drug shares, unity, hard work, closely around the requirements of high-quality development, the trend of movement, from time to time change Externally, accelerate the transformation of business model and profit model, dig deep into the market growth potential, consolidate the traditional business leader position, and innovate the supply chain value-added service model, and, internally, play the financing function, strengthen risk prevention and control, improve the quality of operation, ensure the rapid development of business scale at the same time, improve the quality and efficiency of the company's development
    Nanjing Pharma actively responded to the "4 plus 7" drug band procurement policies, pioneering and innovative 2019, Nanjing Pharma realized operating income of 37.156 billion yuan, an increase of 18.70% YoY; .77%; Net profit on equity was RMB347 million, up 31.26% YoY; total assets were RMB21.966 billion, up 12.33% YoY; and net assets attributable to the owner of the parent company were RMB4,014 million, Year-on-year growth of 9.39 per cent ensured that shareholders' assets were valued and increased
    In 2019, under the correct leadership of Nanjing Pharmaceutical Board of Directors and the support of all shareholders, Nanjing Pharma closely around the overall work ideas and annual target tasks of "looking for opportunities in danger, integrating change, making steady progress, quality and priority", facing the new situation, new requirements, new technologies, new challenges, and actively responding to the "4 plus 7" drug belt procurement, medical insurance payment method reform and other policy impacts, focusing on efforts, innovation and innovation, and innovation Businesses maintain a healthy momentum of development
    Heavy Drug Holdings' "endogenous plus extension" expansion of two paths, further enhance regional synergies and development effects According to the 2019 annual report released by Heavy Drug Holdings, the company achieved operating income of 33.844 billion yuan in 2019, up 31.16% YoY;
    In the face of the deepening of medical reform and the challenges brought about by the procurement of "4 plus 7" band volume, Heavy Drug Holdings continued to strengthen intensive development and innovation transformation last year, promote and improve the national strategic layout, and further enhance the regional synergies through the expansion of the "endogenous plus extension" two paths During the reporting period, the company has completed the investment projects in Dalian and Hainan, the commercial network covers 16 provinces, Anhui, Jilin and other blank regional investment projects were also completed at the beginning of this year, Tianshi marketing, Tiansan pharmaceutical commercial sector mergerand and other key projects in an orderly manner;
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.